Gilead Sciences is a drug manufacturers-general business based in the US. Gilead Sciences stocks (GILD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $69.83 – an increase of 2% over the previous week. Gilead Sciences employs 13,600 staff and has a trailing 12-month revenue of around $25.6 billion.
How to buy Gilead Sciences stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: GILD in this case.
- Research Gilead Sciences stocks. The platform should provide the latest information available.
- Buy your Gilead Sciences stocks. It's that simple.
What's in this guide?
- Can I buy shares in Gilead Sciences?
- Has coronavirus impacted Gilead Sciences shares?
- Gilead Sciences shares summary
- Compare share dealing platforms
- Is Gilead Sciences stock a buy or sell?
- Gilead Sciences performance over time
- Can I short Gilead Sciences shares?
- Is Gilead Sciences suitable for ethical investing?
- Are Gilead Sciences shares over-valued?
- Gilead Sciences's financials
- How volatile are Gilead Sciences shares?
- Does Gilead Sciences pay a dividend?
- Have Gilead Sciences shares ever split?
- Other common questions
How has Coronavirus impacted Gilead Sciences's stock price?
Since the stock market crash in March caused by coronavirus, Gilead Sciences's stock price has had significant negative movement.
Its last market close was $67.43, which is 3.26% down on its pre-crash value of $69.7 and 5.24% up on the lowest point reached during the March crash when the stocks fell as low as $64.07.
If you had bought $1,000 worth of Gilead Sciences stocks at the start of February 2020, those stocks would have been worth $1,094.23 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,016.17.
Gilead Sciences stock priceUse our graph to track the performance of GILD stocks over time.
Gilead Sciences stocks at a glance
|Latest market close||$67.43|
|52-week range||$55.3266 - $70.4|
|50-day moving average||$68.2153|
|200-day moving average||$66.2008|
|Wall St. target price||$74.57|
|Dividend yield||$2.75 (3.93%)|
|Earnings per share (TTM)||$0.24|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Gilead Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gilead Sciences price performance over time
|1 month (2021-06-30)||-2.08%|
|3 months (2021-04-30)||6.24%|
Is Gilead Sciences under- or over-valued?
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's P/E ratio
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 291x. In other words, Gilead Sciences stocks trade at around 291x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.
Gilead Sciences's PEG ratio
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.494. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Gilead Sciences's EBITDA
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$13.3 billion.
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
Gilead Sciences financials
|Revenue TTM||USD$25.6 billion|
|Operating margin TTM||45.69%|
|Gross profit TTM||USD$21 billion|
|Return on assets TTM||11.48%|
|Return on equity TTM||1.33%|
|Market capitalisation||USD$87.6 billion|
TTM: trailing 12 months
How to short and sell Gilead Sciences stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "GILD.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 27.2 million Gilead Sciences stocks held short by investors – that's known as Gilead Sciences's "short interest". This figure is 12.3% up from 24.2 million last month.
There are a few different ways that this level of interest in shorting Gilead Sciences stocks can be evaluated.
Gilead Sciences's "short interest ratio" (SIR)
Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences stocks currently shorted divided by the average quantity of Gilead Sciences stocks traded daily (recently around 6.3 million). Gilead Sciences's SIR currently stands at 4.3. In other words for every 100,000 Gilead Sciences stocks traded daily on the market, roughly 4300 stocks are currently held short.
However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences stocks, or, against the total number of tradable Gilead Sciences stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Gilead Sciences stocks in existence, roughly 20 stocks are currently held short) or 0.0217% of the tradable stocks (for every 100,000 tradable Gilead Sciences stocks, roughly 22 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Gilead Sciences.
Find out more about how you can short Gilead Sciences stock.
Gilead Sciences's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Gilead Sciences's total ESG risk score
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Gilead Sciences's environmental score
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||22.15|
|Total ESG percentile||30.98|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Gilead Sciences stock dividends
Dividend payout ratio: 43.57% of net profits
Recently Gilead Sciences has paid out, on average, around 43.57% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.05% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.05% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.75 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 28 June 2021. The latest dividend was paid out to all shareholders who bought their stocks by 13 June 2021 (the "ex-dividend date").
Have Gilead Sciences stocks ever split?
Gilead Sciences stocks were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Gilead Sciences stocks which in turn could have impacted Gilead Sciences's stock price.
Gilead Sciences stock price volatility
Over the last 12 months, Gilead Sciences's stocks have ranged in value from as little as $55.3266 up to $70.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.3955. This would suggest that Gilead Sciences's stocks are less volatile than average (for this exchange).
Gilead Sciences overview
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Stocks similar to Gilead Sciences
Gilead Sciences in the news
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q2 2021 Results - Earnings Call Transcript
Gilead Sciences, Inc. 2021 Q2 - Results - Earnings Call Presentation
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
How to buy Dole (DOLE) stock in Canada when it goes public
Everything we know about the Dole IPO, plus information on how to buy in.